Literature DB >> 8877031

Expression of CYP3A4, CYP3A5 and CYP3A7 in human duodenal tissue.

K T Kivistö1, G Bookjans, M F Fromm, E U Griese, P Münzel, H K Kroemer.   

Abstract

The essential role of cytochrome P450 3A4 (CYP3A4) in human small intestine is well established, and CYP3A5 seems also to be present in most subjects. However, the role of CYP3A7 in the small intestine remains poorly characterized. We have therefore studied the expression of these CYP3A enzymes in the duodenal tissue from 19 patients, using a specific RT-PCR (reverse transcriptase-polymerase chain reaction) method. CYP3A4 and CYP3A5 were present at the mRNA level in the duodenum of 18 and 19 of the 19 patients studied, respectively. In contrast, mRNA for CYP3A7 was not found in the duodenum in any of the patients. These findings strongly suggest that, unlike CYP3A4 and CYP3A5, CYP3A7 is not expressed in human duodenum.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8877031      PMCID: PMC2042681          DOI: 10.1046/j.1365-2125.1996.42615.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  19 in total

Review 1.  Cytochrome P450 3A and their regulation.

Authors:  Oliver Burk; Leszek Wojnowski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-10-21       Impact factor: 3.000

2.  Cytochromes P450 and MDR1 mRNA expression along the human gastrointestinal tract.

Authors:  Mari Thörn; Niklas Finnström; Stefan Lundgren; Anders Rane; Lars Lööf
Journal:  Br J Clin Pharmacol       Date:  2005-07       Impact factor: 4.335

Review 3.  Cytochrome P450 3A: ontogeny and drug disposition.

Authors:  S N de Wildt; G L Kearns; J S Leeder; J N van den Anker
Journal:  Clin Pharmacokinet       Date:  1999-12       Impact factor: 6.447

Review 4.  HMG-CoA reductase inhibitors and myotoxicity.

Authors:  M Ucar; T Mjörndal; R Dahlqvist
Journal:  Drug Saf       Date:  2000-06       Impact factor: 5.606

5.  Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine.

Authors:  Cheng Li; Dong-Hyun Choi; Jun-Shik Choi
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-01-01       Impact factor: 2.745

6.  Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man.

Authors:  H H Kupferschmidt; K E Fattinger; H R Ha; F Follath; S Krähenbühl
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

7.  Concentrations and effects of buspirone are considerably reduced by rifampicin.

Authors:  T S Lamberg; K T Kivistö; P J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

8.  Effects of ketoconazole and rifampicin on the pharmacokinetics of GLS4, a novel anti-hepatitis B virus compound, in dogs.

Authors:  Xin Zhou; Zhi-wei Gao; Jian Meng; Xiao-yan Chen; Da-fang Zhong
Journal:  Acta Pharmacol Sin       Date:  2013-09-23       Impact factor: 6.150

Review 9.  Effect of hepatic insufficiency on pharmacokinetics and drug dosing.

Authors:  R K Verbeeck; Y Horsmans
Journal:  Pharm World Sci       Date:  1998-10

Review 10.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.